Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GLS-6150

Vaccine (Peptide vaccine) · Immune activation, directed at hepatitis C virus antigens

Phase 1 Most advanced trial (none active)
1 Registered trials

What is GLS-6150?

GLS-6150 is a therapeutic vaccine studied in hepatitis C virus infection. It was evaluated in healthy volunteers and in individuals previously treated for HCV infection across multiple dosing schedules.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
hepatitis C virus antigens (antigen)
Mechanism
Immune activation, directed at hepatitis C virus antigens
Therapy area
Infectious disease
In trials of
INO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03674125 Phase 1 HCV Infection Completed INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HCV Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.